| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Divisions of Cardiology and Rheumatology, University of Vermont College of Medicine, Burlington
Study objectives: To characterize the prevalence of undiagnosed pulmonary hypertension in patients with limited and diffuse scleroderma.
Design: Prospective cross-sectional study.
Setting: University-based outpatient clinic.
Patients: Thirty-four consecutive patients with limited (n=29) or diffuse (n=5) scleroderma but without the clinical diagnosis of pulmonary hypertension.
Measurements and results: All patients had 12-lead ECGs and two-dimensional and Doppler echocardiograms. The pulmonary artery systolic pressure (PAs) was calculated as the sum of the Doppler transtricuspid pressure gradient and the right atrial pressure as estimated by the caval respiratory index. Thirty-three patients (97%) had adequate spectral signals of tricuspid regurgitation. The velocity of tricuspid regurgitation ranged from 1.6 to 4.5 m/s. The calculated PAs ranged from 15 to 95 (mean±SD=30±14 mm Hg). Twelve patients (35% of the total cohort) had pulmonary hypertension defined as PAs of 30 mm Hg or greater.
Conclusions: Undiagnosed elevation of PAs is common in patients with scleroderma. Noninvasive assessment of PAs can be performed accurately in most patients independent of clinical signs of pulmonary hypertension. If successful treatment strategies are identified, it may be possible to identify patients early in the development of pulmonary hypertension and intervene before significant end-organ damage occurs.
Key Words: diagnosis • pulmonary hypertension • scleroderma
Submitted on February 21, 1996
Accepted on July 5, 2007
This article has been cited by other articles:
|
|
 |
|
  L. J. Rubin and D. B. Badesch Evaluation and Management of the Patient with Pulmonary Arterial Hypertension Ann Intern Med, August 16, 2005; 143(4): 282 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Gunen, S. S. Hacievliyagil, F. Kosar, L. C. Mutlu, G. Gulbas, E. Pehlivan, I. Sahin, and O. Kizkin Factors affecting survival of hospitalised patients with COPD Eur. Respir. J., August 1, 2005; 26(2): 234 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hesselstrand, R. Ekman, J. Eskilsson, A. Isaksson, A. Scheja, A.-K. Ohlin, and A. Akesson Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001 Rheumatology, March 1, 2005; 44(3): 366 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Hachulla and J G Coghlan A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism Ann Rheum Dis, September 1, 2004; 63(9): 1009 - 1014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Mukerjee, D St George, B Coleiro, C Knight, C P Denton, J Davar, C M Black, and J G Coghlan Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach Ann Rheum Dis, November 1, 2003; 62(11): 1088 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hesselstrand, A. Scheja, G. Q. Shen, A. Wiik, and A. Akesson The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis Rheumatology, April 1, 2003; 42(4): 534 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Strange, M. Bolster, J. Mazur, M. Taylor, J. R. Gossage, and R. Silver Hemodynamic Effects of Epoprostenol in Patients With Systemic Sclerosis and Pulmonary Hypertension Chest, October 1, 2000; 118(4): 1077 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Egermayer, G I. Town, and A. J Peacock Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension Thorax, February 1, 1999; 54(2): 161 - 168. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
